Table 4.

Time to 2 % target prevalence based on egg-test diagnostics. Shown values represent ensemble mean ± SD of program duration (in years) required to reach a target Schistosoma haematobium infection prevalence ≤ 2 % (T(f _C, τ)), for different choices of coverage (f _c, columns) and inter-treatment periods (τ, rows). Upper panel A shows results for a high risk Kenyan village treated by CWT; Lower panel B – a low risk Kenyan village treated by SBT. Full results for different delivery strategies in high- and low-risk areas are shown in Additional file 5

A.	Community-wide MDA Coverage- High-risk village
Interval	50 %	60 %	70 %	80 %	90 %	100 %
0.5	6.5 ± 1	4.5 ± 0.5	3.5 ± 0.5	3 ± 0.5	2.5 ± 0.5	2 ± 0.5
0.75	19 ± 8	9.5 ± 4	6 ± 1	4.5 ± 0.5	3.5 ± 0.5	3 ± 0.5
1	> 30	23.5 ± 8	11.5 ± 5.5	7 ± 1.5	5.5 ± 1	4 ± 0.5
1.25	> 30	> 30	25 ± 7.5	12.5 ± 5.5	7.5 ± 2	5.5 ± 1
1.5	> 30	> 30	> 30	23.5 ± 7.5	12 ± 6	7.5 ± 1.5
1.75	> 30	> 30	> 30	30 ± 2	20 ± 8	10.5 ± 5
2	> 30	> 30	> 30	> 30	29 ± 3	16 ± 8
2.25	> 30	> 30	> 30	> 30	> 30	24 ± 7.5
2.5	> 30	> 30	> 30	> 30	> 30	29.5 ± 2
2.75	> 30	> 30	> 30	> 30	> 30	> 30
3	> 30	> 30	> 30	> 30	> 30	> 30
ᅟ	ᅟ	ᅟ	ᅟ	ᅟ	ᅟ	ᅟ
B.	School-based MDA Coverage- Low-risk village
Interval	50 %	60 %	70 %	80 %	90 %	100 %
0.5	12.5 ± 11.5	10.5 ± 11.5	8.5 ± 10.5	6.5 ± 10	5.5 ± 9.5	3.5 ± 6.5
0.75	18 ± 11	15 ± 11.5	13.5 ± 12.5	11.5 ± 12	11 ± 12.5	9.5 ± 12
1	25.5 ± 8	19.5 ± 10.5	17 ± 11.5	14.5 ± 12	13.5 ± 12.5	12 ± 12.5
1.25	> 30	26.5 ± 7.5	20.5 ± 10.5	17.5 ± 12	16 ± 12.5	14 ± 12.5
1.5	> 30	> 30	26 ± 7.5	20.5 ± 10.5	18 ± 11.5	16.5 ± 12.5
1.75	> 30	> 30	29.5 ± 3	24 ± 9	20.5 ± 11	18 ± 12
2	> 30	> 30	30 ± 2	28.5 ± 5	23 ± 9.5	19.5 ± 11.5
2.25	> 30	> 30	> 30	29.5 ± 2.5	27 ± 7	21 ± 10.5
2.5	> 30	> 30	> 30	> 30	28.5 ± 5	24 ± 9.5
2.75	> 30	> 30	> 30	> 30	29.5 ± 2.5	27 ± 6.5
3	> 30	> 30	> 30	> 30	> 30	29 ± 4.5